In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, ...
Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research ...
The FDA has granted Breakthrough Device Designation to Bio-Techne's (NASDAQ:TECH) ExoDx Prostate IntelliScore (EPI) test. Breakthrough Device status provides for more intensive guidance on development ...
Bio-Techne Corp. TECH has launched a highly sensitive ESR1 mutation monitoring assay through its Asuragen brand. ESR1 gene mutations are known to be linked to hormone receptor-positive (HR+) ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
(RTTNews) - Gemini Bioproducts, LLC, a supplier of cell culture reagents and process liquids and healthcare private equity firm BelHealth Investment Partners, LLC announced acquisition of selected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback